<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Brain natriuretic <z:chebi fb="7" ids="16670">peptide</z:chebi> (BNP) and N-terminal brain natriuretic <z:chebi fb="7" ids="16670">peptide</z:chebi> (NT-proBNP) are important biomarkers for pediatric <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular diseases</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="7" ids="16670">Peptide</z:chebi> levels are associated with age and gender </plain></SENT>
<SENT sid="2" pm="."><plain>Current studies have shown that BNP and NT-proBNP are valuable in the diagnosis of <z:hpo ids='HP_0001635'>heart failure</z:hpo>, with a high specificity and sensitivity </plain></SENT>
<SENT sid="3" pm="."><plain>They also contribute to differentiating <z:hpo ids='HP_0001635'>heart failure</z:hpo> from <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002098'>respiratory distress</z:hpo> induced by simple pulmonary factors </plain></SENT>
<SENT sid="4" pm="."><plain>In addition, BNP and NT-proBNP are useful in the evaluation of disease severity and treatment guidance in children with <z:hpo ids='HP_0002092'>pulmonary hypertension</z:hpo>, <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> and <z:e sem="disease" ids="C0026691" disease_type="Disease or Syndrome" abbrv="MLNS|MCLS">Kawasaki disease</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Current limitations include the relatively small sample size of the study, the detection method and a range of <z:mpath ids='MPATH_458'>normal</z:mpath> values that are not completely uniform </plain></SENT>
</text></document>